TABLE I.

Patients’ baseline demographics and characteristics. Data are mean ±SE.

	AERD (n = 44)
Age (y)	47 ± 10
Sex (female)	24 (55%)
Race
White	40 (91%)
Black	1 (2%)
Asian	0
Other	3 (7%)
Ethnicity
Hispanic	3 (7%)
FEV1 (L)	3.15 ± 0.11
FEV1 predicted (%)	93.7 ± 2.0
FVC (L)	4.22 ± 0.16
FeNO (ppb)	45 ± 4
Peripheral Eosinophil Count (/μL)	423 ± 53
Peripheral Basophil Count (/μL)	47 ± 8
ACQ-7	0.65 ± 0.09
TNSS	4.5 ± 0.7
Low-dose ICS (≤ 200 mcg*)	15 (34%)
Medium-dose ICS (201–500 mcg *)	18 (41%)
High-dose ICS (>500 mcg*)	4 (9%)
Oral Glucocorticoid Use	2 (5%)
Long-acting Beta Agonist Use	28 (64%)
Long-acting Muscarinic Antagonist Use	0

^*= Fluticasone Propionate dry powder equivalent